Intensity Therapeutics has entered into a clinical trial collaboration agreement with Bristol Myers Squibb. The program will evaluate the safety and efficacy of Intensity’s lead product INT230-6, an investigational, novel and potent anti-cancer drug designed to directly kill cancer cells through intratumoral injection and improve immune cell recognition of cancer, when dosed in combination with Bristol Myers Squibb’s Cytotoxic T Lymphocyte-Associated Antigen 4 immune checkpoint inhibitor Yervoy® (ipilimumab).
“We are excited to have entered into this clinical collaboration with Bristol Myers Squibb, a global leader and pioneer in immuno-oncology,” said Lewis H. Bender, President and CEO of Intensity. “This new collaboration builds upon our other partnerships to evaluate the potential of INT230-6 in combination with immunotherapy.”